ClinicalTrials.gg
CompletedNCT06487572Updated Feb 18, 2025

A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

A Phase 1 interventional study of Risankizumab and Risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Risankizumab
  • ABBV-066
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Body weight greater than 40 kg and less than 100 kg at screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any anti-interleukin-12/23 or anti interleukin-23 treatment for at least one year prior to Screening.
  • Intention to perform strenuous exercise to which the particpant is unaccustomed within one week prior to administration of first dose of study drug and during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Risankizumab Dose A for Intravenous (IV) Infusion

    Participants will receive IV infusion of risankizumab at dose A and then followed for 140 days.

    Drug: Risankizumab

  • Experimental
    Risankizumab Dose B for Subcutaneous (SC) Injection

    Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.

    Drug: Risankizumab

Interventions

  • Intravenous (IV) Infusion

    Also known as: ABBV-066, SKYRIZI

  • Subcutaneous (SC) Injection

    Also known as: ABBV-066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 140 days

  2. Maximum Observed Serum Concentration (Cmax) of Risankizumab

    Cmax of Risankizumab.

    Time frame: Up to approximately 140 days

  3. Time to Cmax (Tmax) of Risankizumab

    Tmax of Risankizumab.

    Time frame: Up to approximately 140 days

  4. Area Under the Serum Concentration-Time Curve (AUC) of Risankizumab

    AUCt of Risankizumab.

    Time frame: Up to approximately Week 4

07

Study locations

2 sites
  • Clinical Pharmacology Of Miami /ID# 268219
    Miami, Florida 33014, United States
  • Acpru /Id# 267057
    Grayslake, Illinois 60030, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Feb 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 5, 2024
StartActual
Jul 23, 2024
Primary completionActual
Feb 7, 2025
CompletionActual
Feb 7, 2025
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06487572
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Jul 23, 2024
Primary completion
Feb 7, 2025
Completion
Feb 7, 2025
Last update
Feb 18, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion